Autoimmune Pancreatitis: Long-term Outcome

Recruiting

• Conditions: Autoimmune Pancreatitis; 10015674

• Registration Number: NL-OMON39923
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 95

Inclusion Criteria

The following patients are eligible for the study:
• All patients diagnosed with AIP according to the ICDC, Asian or HISORT criteria or based on post-surgery histology, a combination of unexplained pancreatic disease, biliary disease/extrapancreatic manifestations and either response to steroids or IgG4-positive serology.
•At least known for more than 2 years with a diagnosis of AIP
•Age > 18 years
•Signed informed consent

Exclusion Criteria

The following patients are excluded from the study:
•Subjects who are unwilling or unable to understand the study and sign the informed consent.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To determine the prevalence of exocrine and endocrine insufficiency in AIP<br /><br>patients.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To evaluate the following aspects of long-term outcome in AIP patients:<br /><br>i. Mortality and cause of death<br /><br>ii. Treatment over time: steroids, other drugs, response and relapses<br /><br>iii. Extrapancreatic manifestations of AIP/IgG4-related disease<br /><br>iv. Malignancy<br /><br>v. Morphology (including changes over time in case multiple imaging sets are<br /><br>available) of the pancreas on imaging<br /><br>vi. Quality of life</p><br>